Elan

Experimental Alzheimer's drug fails to deliver in closely watched clinical trial

By

Alzheimer's researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.